Worldwide Network for Innovation in Clinical Education and Research

What Worldwide Network for Innovation in Clinical Education and Research does

WNICER is a multinational not-for-profit network that conducts clinical research, continuing medical education (CME), and consulting services focused on cardiovascular and chronic diseases, including coronary disease, structural heart disease, heart failure, electrophysiology, cardiac imaging, cardio-oncology, migraine, and inflammatory diseases. The organization operates as a clinician/investigator-based consortium spanning 10 countries, 27 cities, 60+ lead investigators, 400+ team members, and 300+ hospitals serving a population base of over one billion people. It was founded by Dr. Michael E. Farkouh and is led by President & CEO John L. Brooks III, with Dr. Robin L. Smith and Dr. Farouk Mookadam as Senior Advisors and Dr. Verghese Mathew as Director of the Cardiovascular Investigator Program. WNICER is fiscally sponsored by The Cura Foundation, a 501(c)(3) tax-exempt organization (EIN-261150435).

WNICER's core products and services fall into four categories: (1) AI/ML analytics and decision support tools applied to clinical data, big data, and population health research; (2) consulting services covering cardiovascular and cardiometabolic content expertise, bench-to-bedside translation of pharmacologics and medical devices, and healthcare delivery optimization; (3) education programs including COVID-19 and chronic disease webinars, scientific colloquia, CME programming, and roundtable dinner sessions at major cardiology meetings (ACC, AHA, ESC); and (4) clinical trial design, execution, and consulting services including feasibility assessment, sample sizing, registry data analysis, and global site coordination. WNICER has directly contributed to major multinational trials, notably TAILOR-PCI (5,300 patients across 41 locations in 4 countries, published in JAMA in August 2020) and the ATTACC COVID-19 trial (300+ hospitals across 5 continents), and participates in the ACTIV-4 and REMAP-CAP platforms.

WNICER's revenue model reflects its nonprofit status and is diversified across charitable donations (processed via The Cura Foundation as fiscal sponsor), unrestricted educational grants from pharmaceutical and medical device industry sponsors underwriting CME and roundtable events, public research grants (NIH, CIHR, LifeArc, NHMRC, NIHR, HRC, and EU PREPARE/RECOVER consortia) funding trial operations, seed funding for early-career investigators' pilot studies, and consulting engagements. Distribution is community-led and event-driven, leveraging partnerships with academic medical centers (Mayo Clinic, University of Toronto/Peter Munk Cardiac Centre, NYU, Harvard, University of Chicago, University of São Paulo, UNAM), strategic co-sponsorship with the Vatican's Pontifical Council for Culture, and recurring presence at major cardiology conferences. The organization is headquartered at One Rockefeller Plaza, 11th Floor, New York.

Name

Worldwide Network for Innovation in Clinical Education and Research

Legal name

The Worldwide Network for Innovation in Clinical Education and Research

Website

https://wnicer.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

WNICER is a multinational not-for-profit network conducting clinical research, continuing medical education, and consulting services focused on cardiovascular and chronic diseases across a consortium spanning 10 countries, 27 cities, and 300+ hospitals under The Cura Foundation's fiscal sponsorship.

Ownership category

akta.pro rank

Product category

Clinical Research and Medical Education Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)

akta.pro secondary industries

Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

Keywords

• Clinical research network
• Continuing medical education
• Cardiovascular clinical trials
• Medical consulting services
• Global investigator consortium

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Charitable Donations: WNICER operates as a not-for-profit network. Charitable donations are made through its partner and fiscal sponsor, The Cura Foundation, which is a tax-exempt organization under section 501(c)(3) of the Internal Revenue Service Code. EIN: 261150435.
2. Unrestricted Educational Grants from Industry: WNICER receives sponsorship from industry for scientific colloquia, CME programs, and roundtable dinner sessions at major cardiology meetings. The organization also welcomes unrestricted educational grants from industry to develop continuing medical education programs.
3. Research Grants: WNICER provides investigators with seed money towards pilot and feasibility studies that generate preliminary data for national grants (e.g., NIH). The organization welcomes sponsorship from industry and other organizations to fund pilot study initiatives.
4. Consulting Services: WNICER offers consulting services in cardiovascular and cardiometabolic syndromes, bench to bedside translation, healthcare delivery, and clinical program development. Revenue generated supports the organization's mission to improve human health.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

WNICER operates a multinational not-for-profit network that delivers clinical trial design and execution, continuing medical education (CME) programming, scientific colloquia, AI/ML analytics and decision support tools, and clinically relevant consulting services in cardiovascular and cardiometabolic disease. Its offerings are delivered through a consortium of 60+ lead investigators and 400+ team members across 10 countries and 27 cities, addressing coronary disease, heart failure, structural heart disease, electrophysiology, cardiac imaging, cardio-oncology, and related chronic conditions.

Product overview

WNICER operates as a multi-module platform offering clinical research, education, and consulting services. The core offerings include AI Analytics and Decision Support Tools for data-driven healthcare decisions, Consulting Services spanning cardiovascular content expertise and healthcare delivery optimization, Education Programs including CME and scientific colloquia, and Clinical Trials Consulting with global site coordination. WNICER also directly manages clinical research programs and specific trials such as TAILOR-PCI and the ATTACC COVID-19 trial, all delivered through its multinational network of 60+ lead investigators spanning 10 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Consulting Services Expert consulting in cardiovascular and cardiometabolic syndromes providing content expertise, thought leadership, bench-to-bedside translation of pharmacologics and medical devices, and healthcare delivery optimization. Revenue supports the organization's mission to improve human health.
• Education Programs Comprehensive educational offerings including COVID-19 webinars, scientific colloquia, continuing medical education (CME), and late-breaking trial discussions for healthcare professionals and clinician-scientists.
• Clinical Trials Consulting Full-service clinical trial support including feasibility assessment, design, sample sizing, budgets, prospective trial execution, registry data analysis, project management, and partnerships with academic and clinical research organizations.
• Clinical Research Programs Innovative clinical trials, translational research, and implementation strategies that impact clinical care and clinical practice, delivered through WNICER's global site network spanning multiple continents.
• TAILOR-PCI Trial Multi-site, prospective, randomized trial testing pharmacogenomic-guided antiplatelet therapy after PCI, enrolling 5,300 patients in 41 locations across four countries, with results published in JAMA in August 2020.
• ATTACC COVID-19 Trial International clinical trial testing full-dose versus prophylactic anticoagulation in hospitalized COVID-19 patients, demonstrating improved outcomes in moderately ill patients, conducted across 300+ hospitals spanning five continents.

Quantifiable outcome

• TAILOR-PCI trial enrolled 5,300 patients in 41 locations across 4 countries, demonstrating ability to conduct large-scale international clinical trials
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, flagship and regional.

• The Cura FoundationcoreStrategic or Co-development PartnerOne of WNICER's closest strategic partners is The Cura Foundation, a global health movement with the purpose to improve human health. Cura unites public and private sectors, partnering with doctors, patients, business leaders, philanthropists, and thought leaders to create breakthroughs around the world. The Cura Foundation serves as WNICER's fiscal sponsor, handling charitable donations as a tax-exempt 501(c)(3) organization (EIN: 261150435). WNICER is a sponsor of the Cura Foundation and the Vatican's Pontifical Council for Culture's Fifth International Vatican Conference.
• Vatican's Pontifical Council for CultureflagshipStrategic or Co-development PartnerWNICER is a sponsor of the Vatican's Pontifical Council for Culture's Fifth International Vatican Conference. The organization co-hosts events with the Council, including the 'Inflammation: Shared Pathways in Diverse Diseases' think tank event focused on building bridges between disciplines to advance knowledge and public health.
• The Angiogenesis FoundationcoreStrategic or Co-development PartnerThe Angiogenesis Foundation partnered with WNICER and The Cura Foundation to host a fireside chat on long-term effects of COVID-19. Dr. William Li, President, Medical Director and CEO of The Angiogenesis Foundation, participated alongside Dr. Andrew von Eschenbach (Former FDA Commissioner).
• University Health Network (Peter Munk Cardiac Centre)coreStrategic or Co-development PartnerUnder the leadership of Drs. Patrick Lawler and Michael Farkouh, the Peter Munk Cardiac Centre served as a WNICER member and played an integral role in the multinational ATTACC COVID-19 clinical trial, contributing to findings on full-dose blood thinners improving outcomes in hospitalized COVID-19 patients.
• University of Manitoba and CancerCare ManitobacoreStrategic or Co-development PartnerDr. Ryan Zarychanski, associate professor, hematologist and critical care physician at University of Manitoba, chaired the ATTACC platform and the therapeutic anticoagulation domain of REMAP-CAP. This partnership was critical to the multinational COVID-19 clinical trial execution.
• NYU Grossman School of MedicinecoreStrategic or Co-development PartnerDr. Judith Hochman, Harold Snyder Family Professor and chair of ACTIV-4 platform at NYU Grossman School of Medicine, collaborated with WNICER on COVID-19 therapeutic interventions. ACTIV-4 was one of three clinical trial platforms working together on the ATTACC trial.
• Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic is listed as a WNICER member institution participating in clinical research initiatives, including the ATTACC trial.
• University of ChicagocoreStrategic or Co-development PartnerUniversity of Chicago is listed as a WNICER member institution participating in clinical research initiatives, including the ATTACC trial.
• University of São Paulo (InCor Heart Institute)regionalStrategic or Co-development PartnerThe Brazilian clinical network led by Dr. José Nicolau of University of São Paulo's InCor Heart Institute participated in the ATTACC COVID-19 trial as part of WNICER's global network.
• National Autonomous University of MexicoregionalStrategic or Co-development PartnerThe Mexican clinical network led by Dr. Jorge Escobedo of the National Autonomous University of Mexico participated in the ATTACC COVID-19 trial as part of WNICER's global network.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wnicer

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Worldwide Network for Innovation in Clinical Education and Research